JPMorgan analyst Casey Woodring initiated coverage of Alamar Biosciences (ALMR) with an Overweight rating and $30 price target Alamar is a proteomics platform company with a nucleic acid linked immuno-sandwich assay chemistry that is creating a “new gold standard” in protein measurement by combining ultra-high sensitivity with flexible multiplexing and full automation, the analyst tells investors in a research note. JPMorgan views the stock’s current premium valuation as justified and sees room for upside from current levels.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALMR:
- Opening Day: HawkEye 360 jumps in debut after high‑end pricing
- Alamar Biosciences reports Q1 EPS ($1.74) vs. (68c) last year
- Opening Day: Drone maker AEVEX pops on debut
- Cathie Wood’s ARK Investment buys 537.5K shares of Alamar Biosciences today
- Alamar Biosciences opens at $22.60, IPO priced at $17 per share